Tamiflu: useful modern medicine.

uses of Tamiflu

Tamiflu is used to treat symptoms caused by flu virus ( influenza ) . It helps make the symptoms ( e. g. , stuffy nose, cough, sore throat, fever/chills, aches, tiredness ) less severe and shortens recovery time by 1-2 days. Tamiflu is also used to prevent flu if we have been exposed to someone who already has flu ( e. g. , sick household member ) .

Tamiflu works by stopping flu virus from growing. It's not a substitute for the flu vaccine. ( See Notes )

Tamiflu shouldn't be used in infants younger than 1 year of age. Consult your doctor or pharmacist for more details.

how to use of Tamiflu

Read the Patient Information Leaflet available from your pharmacist before you start taking this medicine. If you have any questions, consult your doctor or pharmacist.

Take Tamiflu by mouth as directed by your doctor. You may take it with food or milk to minimize stomach upset. Take this medication as soon as flu symptoms appear or as soon as possible after you have been exposed to the flu. Tamiflu works best if we start taking it within 2 days of either of these events.

If we have the flu, take Tamiflu usually twice a day for 5 days, or as directed by your doctor.

To prevent flu, take Tamiflu usually once a day for at least 10 days, or as directed by your doctor. Follow your doctor's instructions for how long to take this medicine.

Tamiflu works best when amount of medicine in your body is kept at a constant level. Therefore, take Tamiflu at evenly spaced intervals at same time ( s ) every day. Continue to take it for the full time prescribed. Stopping medication too early may allow virus to continue to grow, which may result in a relapse of infection or failure to protect you from the flu.

Inform your doctor if your condition persists or worsens or if new symptoms appear.

side effects of Tamiflu

Nausea and vomiting may occur while use Tamiflu as your body adjusts to this medication and usually go away after 1-2 days. Dizziness may also occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed Tamiflu because he or she has judged that benefit to you is greater than the risk of side effects. Many people using Tamiflu do not have serious side effects.

Tamiflu may rarely cause serious mental/mood changes. This may be more likely in children. Tell your doctor immediately of any signs of unusual behavior including confusion, agitation, self-injury.

Tell your doctor immediately if any of these rare but very serious side effects occur:

A very serious allergic reaction to Tamiflu is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include:

This isn't a complete list of possible side effects. If we notice other effects not listed above, contact your doctor or pharmacist.

precautions of Tamiflu

Before taking Tamiflu, tell your doctor or pharmacist if we are allergic to it; or if you have any other allergies.

Before using Tamiflu, tell your doctor or pharmacist your medical history, especially of:

Tamiflu may make we dizzy; use caution engaging in activities requiring alertness such as driving or using machinery. Limit alcoholic beverages.

Tamiflu should be used only when clearly needed during pregnancy. Discuss risks and benefits with your doctor.

It is not known if Tamiflu passes into breast milk. Consult your doctor before breast-feeding.

interactions of Tamiflu

Your healthcare professionals ( e. g. , doctor or pharmacist ) may already be aware of any possible drug interactions and may be monitoring we for it. Don't start, stop, or change dosage of any medicine before checking with them first.

Before using Tamiflu, tell your doctor or pharmacist of all prescription and nonprescription/herbal products we may use especially of:

Tell your doctor if you have received flu vaccine in nose within 2 weeks before treatment with Tamiflu. Tamiflu may lower your protection from flu vaccine given in the nose. Wait at least 2 days after ending treatment with Tamiflu before receiving flu vaccine given in nose.

This document does not contain all possible interactions. Therefore, before using Tamiflu, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share list with your doctor and pharmacist.

overdose of Tamiflu

If overdose of Tamiflu is suspected, contact your local poison control center or emergency room immediately. US residents can call US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly.

notes of Tamiflu

Don't share Tamiflu with others.

Tamiflu isn't a substitute for flu vaccine. Consult your doctor about the risks and important benefits of receiving a yearly flu shot to lower your chances of getting flu.

missed dose of Tamiflu

If you miss a dose Tamiflu, use it as soon as you remember. If it is within 2 hours of your next dose, skip missed dose and resume your usual dosing schedule. Don't double the dose of Tamiflu to catch up.

storage of Tamiflu

Store Tamiflu at room temperature ( 77 degrees F or 25 degrees C ) away from light and moisture. Brief storage between 59-86 degrees F ( 15-30 degrees C ) is permitted. Don't store Tamiflu in the bathroom. Keep all medicines away from children and pets.

Properly discard Tamiflu when it's expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Tamiflu with US shipping

Pluristem Demonstrates The Potential Of Its PLX Cells To Treat Crohn's Disease And Ulcerative Colitis

Pluristem Therapeutics Inc. ( NasdaqCM: PSTI ) ( DAX: PJT ) , a bio-therapeutics company dedicated to commercialization of non-personalized ( allogeneic ) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced that the Company's PLacental eXpanded ( PLX ) cells have demonstrated in vivo efficacy in treatment of Crohn's Disease and Ulcerative Colitis, collectively termed Inflammatory Bowel Disease ( IBD ) . PLX cells are Pluristem's placental-derived mesenchymal stromal cells ( MSCs ) that have been expanded in Company's proprietary PluriX™ 3-D bioreactor.

Mice and rats each received intrarectal administration of trinitrobenzene sulphonic acid ( TNBS ) , a standard method for inducing IBD in animal models. The macroscopic and microscopic anti-inflammatory effects of intravenous administration of PLX-IBD cells were then evaluated and compared to control animals that received only saline. PLX-IBD cell therapy significantly reduced the TNBS-induced colon lesions both in the macroscopic and microscopic evaluations compared to control animals and to animals given therapy that's currently standard of care in IBD.

Mr. Zami Aberman, Pluristem's President and CEO, commented: " This trial's favorable results, which demonstrate our PLX cells' ability to treat Inflammatory Bowel Disease, as well as our previous studies indicating their potential use to help Multiple Sclerosis patients, show the potential for our PLX cells to treat global autoimmune diseases. We believe that unique capabilities of our PLX cells will lead to cooperative efforts between Pluristem and other significant players in the field of autoimmune diseases to benefit millions of patients. As a cellular therapy, our PLX cells, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source and are stored ready-to-use, could prove to be a readily available therapeutic alternative or addition for these disorders. "

About IBD

Ulcerative colitis and Crohn's disease, known collectively as Inflammatory Bowel Disease ( IBD ) , currently affect 0. 5-1% of Western world's population. This translates to over one million people in America ( 525, 000 Ulcerative Colitis, 490, 000 Crohn's Disease ) and four million people worldwide. Sufferers experience a range of gastrointestinal symptoms, including diarrhea, rectal bleeding and abdominal pain. Children with IBD suffer delayed growth and sexual maturation. Ulcerative colitis is restricted to the colon while Crohn's disease can affect all regions of gastrointestinal tract. Because IBD is chronic and typically has an onset before 30 years of age, patients generally require lifelong treatment. The estimated market for treatment of IBD is over $2 billion.

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized ( allogeneic ) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.

These placental mesenchymal stromal cells ( MSCs ) are expanded in Company's proprietary PluriX ( TM ) 3D bioreactor, which imitates natural microstructure of bone marrow and doesn't require supplemental growth factors or other exogenous materials. Pluristem believes that resultant PLX ( PLacental eXpanded ) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease ( PAD ) . The Company's products in development also include PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation ( BMT ) by improving engraftment of hematopoietic stem cells ( HSCs ) contained in umbilical cord blood; PLX-STROKE, targeting ischemic stroke; PLX-MS, targeting Multiple Sclerosis; and PLX-IBD, targeting patients suffering from Inflammatory Bowel Disease ( IBD ) , which includes Crohn's disease and Ulcerative Colitis.

Pluristem has offices in USA with research and manufacturing facilities in Israel.

Safe Harbor Statement

This press release contains forward-looking statements within meaning of " safe harbor " provisions of Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that this trial's favorable results, which demonstrate our PLX cells' ability to treat Inflammatory Bowel Disease, as well as our previous studies indicating their potential use to help Multiple Sclerosis patients, show the potential for our PLX cells to treat global autoimmune diseases, or that we believe that unique capabilities of our PLX cells will lead to cooperative efforts between Pluristem and other significant players in the field of autoimmune diseases to benefit millions of patients, or that as a cellular therapy, our PLX cells that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source, and are stored ready-to-use, could prove to be a readily available therapeutic alternative or addition for these disorders, we are using forward-looking statements. These forward-looking statements are based on the current expectations of management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology mayn't be validated as we progress further and our methods mayn't be accepted by scientific community; we may be unable to retain or attract key employees whose knowledge is essential to development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory mayn't translate to equally good results in real surgical settings; our patents mayn't be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after date hereof or to reflect occurrence of unanticipated events. For a more detailed description of risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with Securities and Exchange Commission.

Pluristem Therapeutics Inc.

Where to buy quality low priced medicine